Evotaz (Atazanavir + cobicistat)
atazanavir 300 mg + cobicistat 150 mg tablet, 30 · ORAL · PBS code 10692R
STREAMLINEDWhat it costs
AU$339.33 PBS-determined price per 60 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2016-04-01.
- • Repeats: 5.
- • PBS program: CA.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
HIV infection
Initial
Patient must be antiretroviral treatment naive; AND
The treatment must be in combination with other antiretroviral agents.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
HIV infection
Continuing
Patient must have previously received PBS-subsidised therapy for HIV infection; AND
The treatment must be in combination with other antiretroviral agents.
Sponsor: Bristol-Myers Squibb Australia Pty Ltd ABN 33 004 333 322
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.